CSJ117 + GSK3772847

CSJ117 + GSK3772847 is a combination investigational therapy for the treatment of asthma. - **CSJ117** is a fully human antibody fragment (IgG1/λ), delivered as an inhaled dry powder, targeting **thymic stromal lymphopoietin (TSLP)**, a cytokine implicated in allergic and eosinophilic inflammation, aiming to reduce airway inflammation and attenuate the asthmatic response[1][12][17]. - **GSK3772847, also known as melrilimab**, is a monoclonal antibody administered by subcutaneous or intravenous injection, that targets **interleukin-1 receptor-like 1 (IL1RL1, also called ST2 or IL-33R)**, and acts by neutralizing **interleukin-33 (IL-33)**, another key alarmin cytokine in asthma pathogenesis[2][5][11][15]. Both agents are being investigated as add-on therapies for patients with uncontrolled or moderate-to-severe asthma and have demonstrated acceptable safety and pharmacodynamic profiles individually[1][2][5][8][17]. There are no publicly available clinical trials or evidence describing the use of the drugs together as a fixed combination or as a co-administered regimen in asthma or other diseases. The entry represents a potential combination based on the individual mechanisms and indications of both agents.

Other names

melrilimab